ELYM Eliem Therapeutics, Inc.

Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems in the United States. The company's lead clinical-stage candidates include ETX-810, a novel palmitoylethanolamide prodrug that is in Phase IIa clinical trials for the treatment of diabetic peripheral neuropathic pain and pain associated with lumbosacral radiculopathy; and ETX-155 is a neurosteroid GABAA receptor positive allosteric modulator for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures. Its lead preclinical program includes Kv7.2/3 potassium channel opener for epilepsy and pain; and novel analog of 2,3- benzodiazepine for the treatment of generalized anxiety disorder. The company was incorporated in 2018 and is headquartered in Redmond, Washington.

As of 09/30/2022     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  08/06/2021
Outstanding shares:  26,567,681
Average volume:  10,717
Market cap:   $88,470,378
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BMW5LX6
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.55
PS ratio:   0.00
Return on equity:   -50.93%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy